c o m p a n y
play

C O M P A N Y P R E S E N T A T I O N J U L Y 2 0 1 8 WHO ARE WE? - PowerPoint PPT Presentation

Apr 06, 2023 •34 likes •294 views

C O M P A N Y P R E S E N T A T I O N J U L Y 2 0 1 8 WHO ARE WE? A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- Clinical: Breast

  1. C O M P A N Y P R E S E N T A T I O N J U L Y 2 0 1 8

  2. WHO ARE WE? • A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- ‒ Clinical: Breast and Liver based image formation ‒ Geographic: China, France, United States 54 countries 172 employees 23 Aixplorer product approved including 100 in France patent families Revenue and Cumulative Installed Base 1,900 30 000 1,600 2 000 1,300 25 000 1,000 773 1 500 20 000 541 15 000 352 1 000 209 10 000 64 500 5 000 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Cumulative Installed Base Revenue 2 SOURCE: COMPANY

  3. OUR MISSION To become the standard in non-invasive care pathways for breast and liver diseases 3

  4. INNOVATION IN RESPONSE TO A CLINICAL CHALLENGE • A PROVEN TECHNOLOGICAL ADVANCE UltraFast TM Doppler Significantly improved patient throughput THERAPY (15 min vs. 50 min for vascular SCREENING DIAGNOSIS MONITORING examination) • MEASUREMENT OF A NEW UltraFast™ Imaging Real time ShearWave Elastography (SWE™) PARAMETER Up to Real-time, quantitative, any - Tissue stiffness (objective, transducer and any organ 20,000 images/sec reproducible, quantit.) - Replaces manual palpation • NO IONIZING RADIATION Angio PL.U.S. – Planewave ultrasensitive Doppler • NON-INVASIVE EXAMINATION Low flow rates in microvessels without contrast agents • IMPROVED PATIENT THROUGHPUT NEW! TriVu • ULTRAFAST ACQUISITION Real time B,SWE, Col+ simultaneous • 3D ACQUISITION Real-time combination Anatomy and Function 4 SOURCE: COMPANY

  5. HIGH CLINICAL ADDED VALUE FOR A GROWING USER BASE Cumulative total of publications with • GROWING BASE OF CLINICAL DATA Aixplorer 600 (+500 PUBLICATIONS IN PEER-REVIEWED JOURNALS) 500 • EXCELLENT WORLDWIDE NETWORK OF KEY OPINION LEADERS (KOL) 400 • SWE INCORPORATED IN CLINICAL GUIDE 300 LINES (BREAST AND LIVER) • SWE REIMBURSED IN MANY COUNTRIES 200 • VERY POSITIVE FEEDBACK CONCERNING 100 EASE OF USE 0 • MULTIPLE AND REPEAT SALES AT SAME SITE 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 AFTER INITIAL PURCHASE Transformation • HIGH CLINICAL VALUE OF THE TECHNOLOGY RECOGNIZED BY THE FDA : 510K CLEARANCE Technological Innovation FOR LIVER DISEASES , INCLUDING FIBROSIS AND STEATOSIS Clinical Innovation 5 SOURCE: COMPANY

  6. LOCATIONS AND PARTNERSHIP • MORE THAN 2,000 AIXPLORER SYSTEMS INSTALLED WORLDWIDE AND NUMEROUS PRESTIGIOUS PARTNERS 20% 52% 28% Americas/ EMEA Americas EMEA APAC APAC 390 systems 980 systems 530 systems (o/w 280 in the US) (o/w 380 in France) (o/w >390 in China) • CREATION OF A W FOE IN SHANGHAI • CLINICAL ASSESSMENT OF BREAST AND LIVER IN CHINA • - • PRESENCE IN KOREA, CANADA AND TAIW AN, HONG KONG MEXICO SENT FROM THE US • SWITZERLAND, ITALY AND ISRAEL UNDERGOING GROW TH 6

  7. FOCUS • CLINICAL APPLICATIONS ADDRESSING MAJOR PUBLIC HEALTH NEEDS BROAD CLINICAL EXCELLENCE BREAST CANCER • • LEADING CAUSE OF CANCER IN SPECIFICITY OF DIAGNOSIS: BENIGN/MALIGNANT WOMEN: 1 IN 8 WOMEN • OBJECTIVITY OF DIAGNOSIS: NOT OPERATOR DEPENDENT • INCREASE IN NUMBER OF CANCERS: • NO RADIATION • - contraception MONITORING (EVOLUTION OF TUMORS) • SCREENING OF DENSE BREASTS - obesity (>35% WORLD POPULATION) - physical inactivity • SIGNIFICANT DECREASE IN UNNECESSARY BIOPSIES ( -47%)* LIVER DISEASES • SPECIFICITY OF DIAGNOSIS: STAGING OF FIBROSIS • HEP. B & C – FIBROSIS • INTERVENTIONAL IMAGING FOR BIOPSIES - 700 million people • CANCER SCREENING: BENIGN/MALIGNANT - Increasing (diabetes, obesity) • NON-INVASIVE FIBROSIS EVALUATION (HEP B & C) • NAFLD – STEATOSIS • STEATOSIS (NASH) DETECTION - 420 million people • REDUCTION IN USE OF CONTRAST AGENTS (ANGIO PL.U.S) - Increasing fast • LIVER CANCER Screening Diagnosis Monitoring 7 (*): CLINICAL STUDY BE1

  8. CONTINUUM OF LIVER DISEASES Attenuation Angio SWE SWE UFD SWE Speed of sound PLUS Transplantation Viscosity SWE Liver failure Portal hypertension Angio Healthy liver Simple NASH Fibrosis Cirrhosis PLUS Hepatocellular steatosis (Steatohepatitis) SWE carcinoma Inflammation, ballooning PUSH FROM PHARMA COMPANIES CRITICAL CARE PREVENTION NASH THERAPIES ANTIVIRAL THERAPIES  Imaging and treatment of   Evaluation of liver Early detection of non-  Diagnosis of liver fibrosis hepatocellular carcinoma (HCC) steatosis alcoholic fatty liver  Prediction of cirrhosis  Detection and treatment of disease (NAFLD)  Detection of complications complications (ascites, PTH, inflammation & etc.)  Selection of patients for ballooning treatment  Selection of patients for  Diagnosis and transplantation  Management and evaluation of monitoring of patients  Management and monitoring of NASH patients GENERALIST HEPATOLOGY GASTROENTEROLOGY RADIOLOGY 8

  9. A TEC H N OLOGY TH AT C AN BE R EPLIC ATED IN OTH ER C LIN IC AL APPLIC ATION S New cutting-edge technological advances Principal clinical indications for targeted applications Perfusion Perfusion  Visualization and evaluation of  Beyond conventional Doppler without use microvasculature of contrast agents  Diagnosis of hepatic lesions without use of a contrast agent Breast Vascular Vascular  Measurement of pulse wave velocity  Simultaneous indicating vascular elasticity imaging and  Improved work flow for quantifying quantification blood flow rate for better evaluation of cardiovascular diseases Liver Prostate  Better analysis of nodules during early diagnosis  SWE helps to target prostate biopsies to reduce false negatives Musculoskeletal Prostate Musculoskeletal  Real-time visualization of anatomy and functional image of muscle and   Improved Improved tendons biopsy diagnosis guidance 9

  10. F I N A N C I A L D A T A

  11. SOLID GROWTH IN 2017 In thousands of euros 2017 2016 Change (%) • +11% sales growth (+13% constant Products 21,827 20,073 +9% currency) Services 2,869 2,143 +34% • Strong product (+10%*) and service TOTAL SALES 24,695 22,217 +11% (+35%*) performance SALES GEOGRAPHIC DISTRIBUTION • Tremendous growth in china (+33%*) 2016 2017 and France (+16%) EMEA 8 192 • 18%* decline in the united states 9 579 10 310 10 816 37% 43% 42% America 44% 4 446 Asia • Asia and EMEA regions improved 3 569 20% 14% respectively by +29%* and +13% over the year France 5 104 4 403 • Direct sales, which include china, 8 905 21% 20% 7 969 US France and the united states, 36% 36% 3 199 4 048 represent 64% of sales revenues in 13% China 18% 2017, against 64% in 2016 7 487 5 797 RoW 30% 26% (*) =% at constant rate 11

  12. SIGNIFICANT EBITDA IMPROVEMENT • INCREASE IN GROSS MARGIN AND SIGNIFICANT EBITDA IMPROVEMENT 31/12/2017 31/12/2016  Var. 11% sales growth In thousands of euros Sales 24,695 22,217 +11.2%  gross margin rate on sales improvement: - 1,023 - Other revenue +1.7pt Total revenue 24,695 23,240 +6.3% control of OPEX with € 21.0m vs. 20.9m in  -13,608 -12,628 +7.8% Cost of sales 2016 Gross margin 1 11,088 10,611 +4.5%  intensification of R&D efforts in accordance Gross margin on sales 2 11,088 9,588 +15.6% with next platform’s development phasing with 44.9% 43.2% +1.7pt € 9.8m spent ( € 2.6m net of RTC and Gross margin as a % of sales activation) vs € 9.1m in 2016 Research and development -2,558 -3,046 expenses EBITDA improvement of + € 1.2m  -12,341 -11,987 Selling and marketing expenses  improvement in the operating result with General and administrative -5,775 -5,447 expenses € (9.9m) vs. € (10.3m) in 2016 (-40% vs. -46% Other operating -294 -403 of sales) income/(expense) Total OPEX -20,968 -20,883 - € 2.2m decrease in financial result  EBITDA -6,611 -7,805 +15.3% - € 0.9m for early Norgine loan repayment and interests on -9,880 -10,272 +3.8% Core operating result repayable advance, non-recurring charge specific to 2017 - € 0.8m due to exchange gain on 2016 and loss on 2017 Operating result -9,880 -10,272 +3.8% - € 0.4m due to rise in financial interests Financial result -2,405 -221 - Net profit/(loss) -12,247 -10,555 -16.0% (1) GROSS MARGIN ON SALES = SALES - COST OF SALES 12 (2) GROSS MARGIN ON SALES = SALES - GROSS MARGIN ON SALES/SALES

Recommend

More recommend